Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus FORBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus FORBAXIN.
COR-OTICIN vs FORBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 drops in each affected ear twice daily for 7 days.
IV: 500 mg every 12 hours, infused over 30 minutes.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal (60-70% unchanged), biliary/fecal (20-30%)
Category C
Category C
Topical Corticosteroid + Antibiotic
Antibiotic